Novo Nordisk buys into NLRP3 program for potential $700m 06-Oct-2022 By Ben Hargreaves The Danish company becomes the latest large pharma company to invest in NLRP3 assets, with these types of treatments holding the potential to treat a variety of diseases linked to inflammation.